Will Thompson
@will-thompson96.bsky.social
Final year medchem PhD student studying novel MOA degraders #TPD
🎓🐔 Newcastle University
🎓🐣 University of Bath
🎓🥚 University of Glasgow
🤓📚📷🎨📽️🏳️🌈 he/him
linkedin.com/in/will-thompson96/
🎓🐔 Newcastle University
🎓🐣 University of Bath
🎓🥚 University of Glasgow
🤓📚📷🎨📽️🏳️🌈 he/him
linkedin.com/in/will-thompson96/
Great initiative from @harrietsg.bsky.social and @sjharnor.bsky.social here!
Check it out to find out about the human aspect of science ❤️ Why we do what we do and how we feel about it all
Check it out to find out about the human aspect of science ❤️ Why we do what we do and how we feel about it all
Will Thompson (@will-thompson96.bsky.social), PhD Student (Medicinal Chemistry), Newcastle University, UK #facesofscience #chemsky #sciencesky
May 19, 2025 at 7:56 PM
Great initiative from @harrietsg.bsky.social and @sjharnor.bsky.social here!
Check it out to find out about the human aspect of science ❤️ Why we do what we do and how we feel about it all
Check it out to find out about the human aspect of science ❤️ Why we do what we do and how we feel about it all
A couple weeks into writing up and I'm enjoying it about as much as I expected - actually quite a lot
May 16, 2025 at 7:47 AM
A couple weeks into writing up and I'm enjoying it about as much as I expected - actually quite a lot
It's concerning that we're at a point where I'm reconsidering conference attendance due to political situations 😬 maybe ACS fall isn't meant to be this year
March 26, 2025 at 11:37 AM
It's concerning that we're at a point where I'm reconsidering conference attendance due to political situations 😬 maybe ACS fall isn't meant to be this year
I don't want to think about how long it took to make this... Elacestrant (racemic). £700 for 10mgs and I finally have 1.5g. Do I finish the PhD or just sell it and make a run for it?
March 25, 2025 at 7:25 AM
I don't want to think about how long it took to make this... Elacestrant (racemic). £700 for 10mgs and I finally have 1.5g. Do I finish the PhD or just sell it and make a run for it?
Reposted by Will Thompson
The problem with that "First they came for" poem is it makes a lot of unlikely assumptions. For example it assumes they would ever come for me
March 17, 2025 at 12:54 PM
The problem with that "First they came for" poem is it makes a lot of unlikely assumptions. For example it assumes they would ever come for me
Big news for #TPD field, ARV-471 vs fulvestrant for ER degradation.
I'll be interested to see PROTACs pitted against inhibitors rather than existing degraders next
I'll be interested to see PROTACs pitted against inhibitors rather than existing degraders next
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial | Arvinas
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – V...
ir.arvinas.com
March 13, 2025 at 9:13 AM
Big news for #TPD field, ARV-471 vs fulvestrant for ER degradation.
I'll be interested to see PROTACs pitted against inhibitors rather than existing degraders next
I'll be interested to see PROTACs pitted against inhibitors rather than existing degraders next
Reposted by Will Thompson
How do you decide on colors for your #ACSSpring2025 poster? Check out these tips for creating posters that stand out and are accessible.
March 7, 2025 at 3:35 PM
How do you decide on colors for your #ACSSpring2025 poster? Check out these tips for creating posters that stand out and are accessible.
So many TACs! Excited to see what new stuff we can come up with now we seem to be really mastering the induced proximity space
Congratulations to Kat Kayser-Bricker and the Halda team on leading the efforts to advance RIPTACs to clinic! Also commentary from @danetteldaniels.bsky.social on what this means for the field as well as work being done at Foghorn in this space.
www.nature.com/articles/d41...
www.nature.com/articles/d41...
Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
Halda Therapeutics has started a clinical trial of its first-in-modality RIPTAC drug HLD-0915 in prostate cancer, to see if bifunctional drugs can provide tissue-specific activity.
www.nature.com
March 5, 2025 at 12:32 PM
So many TACs! Excited to see what new stuff we can come up with now we seem to be really mastering the induced proximity space
Highlighting some great lab mates ❤️
COMING SOON! Sneak preview of the selection of people we're showcasing this month 🧪
March 4, 2025 at 6:02 PM
Highlighting some great lab mates ❤️
Finally properly moved over from Twitter...not that I'd used it in years anyway.
Glad to see this is so much more active than when I first got my account a year or so ago!
Glad to see this is so much more active than when I first got my account a year or so ago!
March 4, 2025 at 3:04 PM
Finally properly moved over from Twitter...not that I'd used it in years anyway.
Glad to see this is so much more active than when I first got my account a year or so ago!
Glad to see this is so much more active than when I first got my account a year or so ago!